For Patients.
We believe that Minimal Residual Disease (MRD) monitoring can be an important predictor of disease progression and relapse after treatment and provide peace of mind for patients. We believe that designing a highly sensitive test that does not require bone marrow aspiration will make it more accessible. That’s why we are developing EasyM.
We believe that Minimal Residual Disease (MRD) monitoring can be an important predictor of disease progression and relapse after treatment and provide peace of mind for patients. We believe that designing a highly sensitive test that does not require bone marrow aspiration will make it more accessible. That’s why we are developing EasyM.
Overview.
Standards for MRD testing and standards of care are still emerging. EasyMTM is certified for clinical use under CLIA and we are seeking further approvals through FDA and Health Canada. Unfortunately, EasyM is not yet covered by private or public health insurance.
If you would like to receive EasyM testing, please have your doctor contact us.
If you want to see more widespread use of MRD testing for Multiple Myeloma you can:
- Talk to you doctor
- Explore clinical trials for myeloma drugs and consider enrolling in one that uses EasyM or another MRD technique
- Join the discussion at local conferences such as the Myeloma Scientific Roundtable
- Sign up for updates from EasyM
Clinical Use.
EasyM has been approved as a Laboratory Developed Test (LDT) by CLIA/COLA in all US states except CA, NY, RI, PA and MD. We are seeking further certification in the remaining states, by the US FDA and by Health Canada.
If you’d like to receive our news and updates as we progress EasyM into a widely available clinical test, please follow us on LinkedIn and/or sign up below.